Related Experiment Videos
Hypoglycaemic activity of Pterocarpus marsupium Roxb
S P Dhanabal1, C K Kokate, M Ramanathan
1Department of Pharmacognosy, University College of Pharmaceutical Sciences, Kakatiya University, Warangal 506 009, Andhra Pradesh, India. dhanskanaksahil@rediffmail.com
Phytotherapy Research : PTR
|January 7, 2006
Summary
Pterocarpus marsupium bark extract shows significant antidiabetic effects in rats. The butanol subfraction effectively controls blood glucose and improves metabolic alterations, potentially mimicking insulin action.
Area of Science:
- Pharmacology and Phytochemistry
- Metabolic Disorders Research
Background:
- Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.
- Management of diabetes often involves addressing associated metabolic alterations like dyslipidemia and liver dysfunction.
- Pterocarpus marsupium (Vijayasara) is a traditional medicinal plant with a history of use in managing diabetes.
Purpose of the Study:
- To evaluate the antidiabetic activity of different subfractions of Pterocarpus marsupium alcohol extract.
- To assess the impact of these subfractions on lipid profiles and liver function tests in diabetic rats.
- To identify the most potent subfraction for managing diabetes-related metabolic complications.
Main Methods:
- Alloxan-induced diabetic rat model was used to assess antidiabetic efficacy.
- Alcohol extract of Pterocarpus marsupium bark was fractionated.
- Key biochemical parameters including plasma glucose, total protein, cholesterol, triglycerides, alkaline phosphatase, SGOT, and SGPT were measured.
Main Results:
- Pterocarpus marsupium extract significantly impacted plasma glucose levels in diabetic rats.
- The butanol subfraction demonstrated superior antidiabetic activity compared to other fractions.
- Extracts effectively modulated lipid profiles and liver enzymes, indicating control over metabolic alterations.
Conclusions:
- The butanol subfraction of Pterocarpus marsupium alcohol extract possesses significant antidiabetic properties.
- This subfraction not only reduces hyperglycemia but also ameliorates diabetes-associated metabolic disturbances.
- The observed activity suggests potential insulin-like properties of Pterocarpus marsupium.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...